The effects of orally ingested dihomo---linolenic acid (DHLA), the natural biosynthetic precursor of prostaglandin El (PGE,), were assessed in human volunteers. Single doses of DHLA (0 1-2g) increased the proportion of DHLA relative to arachidonic acid in plasma and platelets and also increased the ex-vivo capacity of platelets to produce PGE, and PGE2. More pronounced effects were observed during sustained treatment (five days to four weeks) when DHLA also accumulated in red cell membranes. These biochemical changes were accompanied by potentially antithrombotic changes in haemostatic function. The most common effect, which was consistently detected after 0 1-g single doses of DHLA or its methyl ester, was a decrease in plasma heparin-neutralising activity. Inhibition of platelet aggregation induced by adenosine diphosphate was also detected, though this was generally less pronounced. Sustained treatment in one subject also produced definite inhibition of ristocetininduced platelet aggregation. There was only one possible adverse effect-a transient cough in a subject with a history of asthma.
Introduction
Recent advances in the understanding of the roles of prostaglandins in platelet function have suggested new possibilities for therapeutic intervention in human thromboembolic disease. This report is concerned with one such possibility-the use of dihomo-y-linolenic acid (DHLA), a naturally occurring polyunsaturated fatty acid which is the biosynthetic precursor of prostaglandin El (PGE I).
When platelets are appropriately stimulated, prostaglandinprecursor fatty acids are mobilised from phospholipid pools. These fatty acids are metabolised to various prostaglandins and related products, which have different modulating effects on platelet function.1 Metabolic pathways of the precursor fatty acids DHLA and arachidonic acid (AA) are shown in fig 1. The relative amounts of DHLA and AA in platelets and other tissues are determined largely by dietary constituents and the degree to which DHLA is converted to AA. In most tissues, including platelets, there is much more AA than DHLA. Probably because of this, and because both fatty acids compete for the enzyme cyclo-oxygenase, metabolites of AA, such as the strongly proaggregatory thromboxane A, (TxA,) , are generated in preference to metabolites of DHLA such as PGE,. DHLAderived PGE, is one of the most potent known inhibitors of platelet function and has other properties that make it attractive as a potential antithrombotic agent: it produces vasodilatation, promotes increased red cell flexibility in vitro,' and inhibits the development of artificially induced arterial thrombosis in Single doses of DHLA were followed by dose-related increases in plasma DHLA: AA ratios (fig 2) . Maximum ratios occurred three to five hours after dosing, with a secondary peak at six to 24 hours. Similar changes were seen in platelets. The two plasma peaks corresponded, respectively, to the appearance of DHLA in triglycerides and phosphatidyl choline. AA concentrations did not increase significantly in either plasma or platelets. DHLA esters seemed to be more poorly absorbed than the free acid. In the sustained-treatment studies DHLA penetrated additional lipid pools; cumulative increases in plasma and platelet DHLA: AA ratios were accompanied by increases in the ratio in red cell membranes. DHLA accumulated predominantly in phosphatidyl choline, but there was some accumulation in phosphatidyl ethanolamine. Small increases in the AA content of plasma, but not platelets, were sometimes detected. Tests of haemostasis were generally carried out as previously described.6 Plasma heparin-neutralising activity was measured using one or more of three different methods.7 Platelet aggregation was studied using either a Born mark III aggregometer or a Payton module. Blood used for preparing platelet-rich plasma was routinely collected into 3 86, trisodium citrate (1 part citrate to 9 parts blood), although very occasionally tests were carried out with half-strength citrate and with an unadjusted platelet count. Platelet-rich plasma platelet counts were adjusted to the range 200-250 10'9/1. Chemical and haematological values were followed using standard automated techniques. Plasma, platelet, and red cell DHLA and AA concentrations were estimated by gas-liquid chromatography after transmethylation to produce the methyl ester. The capacity of platelets in plateletrich plasma to produce PGEI and PGE2 was assessed by maximal stimulation with bovine thrombin (20 U/ml for 5 min at 37 C). After isolation"' the prostaglandins were estimated by bioassay.
Experiniettal design-In the single-dose studies (table 1) the dose was taken at 9.30 am and blood samples were taken every one to two hours for six hours and then less often for up to 48 hours. In the sustained-dosing studies (table 1) blood was usually sampled four hours after the morning dose. Occasionally the effects of single doses were followed at the beginning and end of periods of sustained treatment.
In all experiments the volunteers ate a breakfast low in saturated fats throughout the test period. No other dietary restriction was imposed.
In the sustained-treatment studies in cases 1 and 2 vitamin E 3 mg was taken with each dose of DHLA and continued in a dose of 3 mg/day until blood sampling was stopped. The capacity of platelets to produce PGEl and PGE2 was estimated in eight of the single-dose studies. In each case there was a transient increase in PGE, production during the first six hours after dosing (55",, mean rise); in six cases this increase was coincident with an increase in PGE2 production (33", mean rise). These changes were not clearly dose related. Platelet prostaglandins were assayed during the three sustained dosing studies in which a daily dose of 1 g or more DHLA was used. Increases in PGEl production were more pronounced than after single doses; they were also sustained during the treatment period, coincident with changes in plasma and platelet DHLA: AA ratios (fig 3) and generally accompanied by parallel but less considerable increases in PGE2 production.
HAEMOSTASIS
The principal changes in both the single-dose and the sustainedtreatment studies were a decrease in plasma heparin-neutralising activity and an inhibition of platelet aggregation induced by adenosine diphosphate (ADP) (fig 4) . Neither of these effects occurred during placebo studies. Single doses of DHLA or its esters were followed by a decrease in heparin-neutralising activity in 12 of the 15 studies. The two subjects who did not respond (cases 2 and 8) both had low basal levels of heparin-neutralising activity. The decrease in this activity was usually greatest four to six hours after dosing. There was no correlation between the size of the dose and the magnitude of the effect, which was clearly seen after all the single doses of 0-1 g. The duration of the effect, however, did seem to be related to the dose: after 0 1 g doses heparin-neutralising activity had always returned to baseline values by 24 hours, while the effects of larger doses were generally maintained at this time. Sustained treatment at all dose levels resulted in cumulative effects in six of the seven studies, the exception being the study on case 2. Positive effects were maintained for at least several days after dosing had been stopped. ADP-induced platelet aggregation (0 25-2 5 1mmol) was inhibited in nine of the 15 single-dose studies. The effect showed a similar time course to the reduction in heparin-neutralising activity but was less pronounced and usually did not persist for 24 hours. Effects were generally most pronounced after doses of 1 g or more. In the sustained treatment studies effects on aggregation varied between different subjects: when positive effects were seen these were greater than after single doses. Of the four 0l1-g studies aggregation was inhibited with free acid only in case 3, in whom a cumulative effect was apparent by the fifth day. In two of the three studies in which at least 1 g was given daily there was considerable and cumulative inhibition of ADPinduced aggregation (fig 4) , which was coincident with increased platelet PGE, production.
In one of these two studies (case 1; fig 3) a wider panel of haemostatic tests was undertaken. His aggregation responses to ristocetin (1 5 mg ml) and adrenaline (2 5 ,amol) were also found to be inhibited. The response to ristocetin took almost four weeks to return to baseline values, and inhibition of ADP and adrenaline-induced aggregation was also still evident at this time. In this subject there were no effects on the bleeding time, in-vivo platelet adhesion,1' platelet glass bead retention, factor VIII concentration, factor VIII-related antigen, or plasma concentrations of ristocetin cofactor. In the third study, where at least 1 g of DHLA was given daily (case 2) neither inhibition of aggregation nor a fall in heparin-neutralising activity could be detected despite significant increases in plasma and platelet DHLA: AA ratios. Although increases in platelet PGEl production and the PGE,I PGE, ratio were observed in this subject, the increases were much smaller than those measured in the two other comparable studies.
CLINICAL MONITORING There were no changes in chemical or haematological values that could be attributed to DHLA. Only once was a possibly related clinical adverse effect observed-a transient cough that occurred in case 5 about four hours after a single dose of 1 g DHLmethyl ester. This subject had a personal and family history of asthma and, interestingly, had had a similar reaction some years earlier after receiving intravenous PGE,.
Discussion
This study shows that it is possible to manipulate platelet prostaglandin biosynthesis in man using the natural prostaglandin precursor for PGE1 and that the changes induced are accompanied by potentially antithrombotic changes in haemostasis. DHLA was well tolerated when given orally, accumulated in lipid pools, and was accessible as a substrate for prostaglandin biosynthesis. Although increases in the capacity of platelets to produce PGEI may have accounted in part for the effects of DHLA on haemostasis, its precise mechanism of action has still to be defined. A puzzling finding was the rise in the capacity of platelets to produce PGE2, which occurred in the absence of evidence of appreciable conversion of DHLA to AA, the biosynthetic precursor of PGE2. One possible explanation is that DHLA or its metabolites, or both, may inhibit conversion of PGH2 to the strongly proaggregatory TxA2 1 12 and therefore redirect the conversion of PGH2 to its prostanoate metabolites PGE2, PGD, , and PGI2 (prostacyclin) . The last two substances are potent inhibitors of platelet aggregation.i3 ii
The most impressive change in haemostasis was the reduction in heparin-neutralising activity produced by very small doses of DHLA. Plasma heparin-neutralising activity has been found to be high in various thrombotic states, including coronary heart disease and venous thrombosis.8 1i The extent to which heparin-neutralising activity reflects basic pathological mechanisms is unknown; one view is that it represents, at least partly, the activity of platelet factor 4 released from platelets.'5 A reduction in heparin-neutralising activity may therefore indicate inhibition of the platelet release reaction. The role of platelet factor 4 in vivo is uncertain, but one possibility is that increased concentrations may have prothrombotic effects mediated through increased thrombin generation.
Although inhibition of platelet aggregation was less consistent than the fall in heparin-neutralising activity, the effect generally correlated well with changes in lipid and prostaglandin biochemistry, which at least partly explained the lack of response in case 2. Sim and McCraw"6 recently reported severe inhibition of ADP-induced platelet aggregation after 0 1-g doses of DHLmethyl ester and suggested that the methyl ester may be more active than the free acid. We do not agree with this suggestion and believe that the discrepancy between our findings and those of Sim and McCraw is probably due to factors such as individual subject variation or differing experimental conditions. The most surprising finding in the aggregation studies was the inhibition of ristocetin-induced aggregation during the sustained dosing study in case 1. Lack of aggregation to ristocetin is characteristically associated with von Willebrand's disease, in which there is evidence of defective adhesion of platelets to subendothelium'7 and, in pigs, resistance to experimentally induced atherosclerosis." Inhibition of ristocetin-induced aggregation therefore suggests that DHLA may have an inhibitory effect on platelet-vessel wall interaction, a probable early event in the formation of arterial thrombi. No other features of von Willebrand's disease were detected.
Diets low in saturated fats and rich in polyunsaturated fats (predominantly linoleic acid) both lower heparin-neutralising activity1 and reduce platelet aggregability.2 Since linoleic acid is a precursor of DHLA (fig 1) both these effects may be mediated through its conversion to DHLA. Such diets have also been reported to reduce mortality due to atherosclerosis,21 and partial substitution of dietary saturated fats by polyunsaturated fats has been widely recommended as a means of reducing the risk of coronary heart disease.22 23 Perhaps small doses of DHLA may be equally if not more effective than major dietary manipulations in preventing and treating these conditions.
Introduction
Increased destruction of red cells in "warm" immune or autoimmune haemolytic anaemia (AIHA) is commonly associated with a positive direct antiglobulin test (DAGT) result, usually because of the presence of either IgG alone or IgG and complement on the surface of the red cells. Some patients have all the clinical features of AIHA, but no antibody can be detected on the red cells by the direct antiglobulin test.1'-:' By using the sensitive antiglobulin consumption technique, however, small quantities of antibody belonging to the IgG class have been shown on the red cells of some patients with a negative DAGT result.' Most patients with AIHA have a raised reticulocyte count at presentation-a reflection of the high erythroid turnover that occurs to compensate for the anaemia and anoxaemia.
Crosby and Rappaport,5 however, noted the occurrence of reticulocytopenia in AIHA, and Pirofsky:3 also reported a low reticulocyte count in some patients with this disorder whose bone-marrow aspirate was normal or hyperplastic.
We report on three patients who had haemolytic anaemia with some unusual features. Neither IgG antibodies nor complement
